Abstract
On June 8, 2006, Food and Drug Administration in the USA approved quadrivalent vaccine against HPV 6, 11, 16 and 18 types as "the first and the one and only vaccine against cervical cancer, cervical, vulvar and vaginal precancerosis caused by HPV 16, 18, and as the prevention against genital warts and cervical laesions of low grade, caused by HPV 6, 11, 16 and 18, for girls and women in the age of 9-26 years". At the time, two vaccines are routinely used: quadrivalent Silgard (Gardasil) and bivalent Cervarix.
National immunization programmes in many countries practice general vaccination, indications and recommendation for vaccination of boys become broader, maximum age limit has not been set. In some countries vaccination of the naive girl's population reaches 80 %, data exist on high efficiency of both vaccines against cervical precancerosis, community protection against genital warts in Silgard and enlarged cross-protection in Cervarix.
First data of efficiency against cancers at other localisations also emerge. Since 2012, vaccination of girls at the age of 13-14 years has been covered from the health insurance in the Czech Republic.
In 2014 successively, the 2-dose schedule is implemented for girls at the age of 9-14 years in bivalent and for boys and girls at the age of 9-13 years in quadrivalent vaccine. During 8 years, many doubts, myths, distortions and mistakes in use and comparison of antiHPV vaccines also appeared.
In the paper, the controversial issues were actualized according to the contemporary Summaries of Product's Characteristics.